Evolus, Inc. ( EOLS) - Key Metrics
EOLS Revenue per Share metrics
| Date | Revenue per Share | Net Income per Share | Operating Cash Flow | Free Cash Flow per Share |
|---|---|---|---|---|
| 2026Q2 | $1.28 | -$0.12 | -$0.05 | -$0.04 |
| 2026Q1 | $1.12 | -$0.16 | -$0.15 | -$0.18 |
| 2025Q4 | $1.40 | $0 | $0.20 | $0.17 |
| 2025Q3 | $1.07 | -$0.24 | -$0.23 | -$0.26 |
| 2025Q2 | $1.08 | -$0.27 | -$0.38 | -$0.42 |
EOLS Payout ratio and Price per Earnings ratio
| Date | Payout ratio | PE ratio |
|---|---|---|
| 2026Q2 | 0% | -14.46 |
| 2026Q1 | 0% | -6.42 |
| 2025Q4 | 0% | 831.25 |
| 2025Q3 | 0% | -6.40 |
| 2025Q2 | 0% | -8.53 |
EOLS
Price: $7.10
52 week price:
Earnings Per Share: -0.53 USD
Exchange: NGM
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Country: United States
Volume: 16622
Market Capitalization: 470.2 million